EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection

Presented by

Synopsis

Summary: Hepatitis B virus (HBV) infection remains a global public health problem with changing epidemiology due to several factors including vaccination policies and migration. This Clinical Practice Guideline presents updated recommendations for the optimal management of HBV infection. Chronic HBV infection can be classified into five phases: (I) HBeAg-positive chronic infection, (II) HBeAg-positive chronic hepatitis, (III) HBeAg-negative chronic infection, (IV) HBeAg-negative chronic hepatitis and (V) HBsAg-negative phase. All patients with chronic HBV infection are at increased risk of progression to cirrhosis and hepatocellular carcinoma (HCC), depending on host and viral factors. The main goal of therapy is to improve survival and quality of life by preventing disease progression, and consequently HCC development. The induction of long-term suppression of HBV replication represents the main endpoint of current treatment strategies, while HBsAg loss is an optimal endpoint. The typical indication for treatment requires HBV DNA [2,000 IU/ml, elevated ALT and/or at least moderate histological lesions, while all cirrhotic patients with detectable HBV DNA should be treated. Additional indications include the prevention of mother to child transmission in pregnant women with high viremia and prevention of HBV reactivation in patients requiring immunosuppression or chemotherapy. The long-term administration of a potent nucleos(t)ide analogue with high barrier to resistance, i.e., entecavir, tenofovir disoproxil or tenofovir alafenamide, represents the treatment of choice. Pegylated interferon-alfa treatment can also be considered in mild to moderate chronic hepatitis B patients. Combination therapies are not generally recommended. All patients should be monitored for risk of disease progression and HCC.
Treated patients should be monitored for therapy response and adherence. HCC remains the major concern for treated chronic hepatitis B patients. Several subgroups of patients with HBV infection require specific focus. Future treatment strategies to achieve ‘cure’ of disease and new biomarkers are discussed.

Keywords: Hepatitis B; EASL guidelines; Treatment; Interferon; Entecavir; Tenofovir; TAF; HBsAg; Hepatocellular carcinoma; HBV DNA; HBV reactivation; Mother to child transmission.

Available Languages

English

Source File

Publishing organization(s):

EASL European Association for the Study of the Liver

Scientific area:

Hepatobiliary
 


This item can be cited as: Journal of Hepatology 2017 vol. 67 j 370–398; PMID 28427875

You may be interested in:

New drugs
English, Presentation, Hepatobiliary, 2016, Histopathology, Paediatrics, Surgery, Gut Microbiota
Prediction of response to treatment in hepatitis B and hepatitis C
English, Presentation, Clinical aspects, Medical management, Liver, Viral hepatitis, Hepatology, 2012

Categorisation:

  • Format
    • Standards and Guidelines
  • Language
    • English
  • UEG Member Society
    • European Association for the Study of the Liver (EASL)
  • UEG Week Pathway
    • Hepatobiliary
  • Year
    • 2017